Synagis
E474951
Synagis is a monoclonal antibody medication used to help prevent serious lower respiratory tract infections caused by respiratory syncytial virus (RSV) in high-risk infants and young children.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Synagis canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T4850533 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Synagis Context triple: [MedImmune, notableProduct, Synagis]
-
A.
oseltamivir
Oseltamivir is an oral antiviral medication (commonly known by the brand name Tamiflu) used to treat and prevent influenza, including pandemic strains such as 2009 H1N1.
-
B.
Gardasil
Gardasil is a widely used human papillomavirus (HPV) vaccine that helps prevent cervical and other HPV-related cancers and diseases.
-
C.
zanamivir
Zanamivir is an inhaled neuraminidase inhibitor antiviral drug used to treat and prevent influenza A and B infections, including strains such as the 2009 H1N1 virus.
-
D.
Opekta
Opekta was a German-Dutch company that produced and sold pectin-based gelling agents for making jam, notably managed in its Amsterdam branch by Anne Frank’s father, Otto Frank.
-
E.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Synagis Target entity description: Synagis is a monoclonal antibody medication used to help prevent serious lower respiratory tract infections caused by respiratory syncytial virus (RSV) in high-risk infants and young children.
-
A.
oseltamivir
Oseltamivir is an oral antiviral medication (commonly known by the brand name Tamiflu) used to treat and prevent influenza, including pandemic strains such as 2009 H1N1.
-
B.
Gardasil
Gardasil is a widely used human papillomavirus (HPV) vaccine that helps prevent cervical and other HPV-related cancers and diseases.
-
C.
zanamivir
Zanamivir is an inhaled neuraminidase inhibitor antiviral drug used to treat and prevent influenza A and B infections, including strains such as the 2009 H1N1 virus.
-
D.
Opekta
Opekta was a German-Dutch company that produced and sold pectin-based gelling agents for making jam, notably managed in its Amsterdam branch by Anne Frank’s father, Otto Frank.
-
E.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
biologic drug
ⓘ
medication ⓘ monoclonal antibody ⓘ |
| bindsTo | RSV F protein ⓘ |
| hasActiveIngredient | palivizumab ⓘ |
| hasApprovalYear | 1998 ⓘ |
| hasATCCode | J06BB16 ⓘ |
| hasBrandName | Synagis NERFINISHED ⓘ |
| hasDosage | 15 mg/kg once monthly ⓘ |
| hasFormulation | solution for injection ⓘ |
| hasGenericName | palivizumab NERFINISHED ⓘ |
| hasIndication |
prevention of RSV disease in high-risk infants
ⓘ
prevention of RSV disease in high-risk young children ⓘ prevention of serious lower respiratory tract infection caused by respiratory syncytial virus ⓘ |
| hasLegalStatus | prescription only ⓘ |
| hasMechanismOfAction | neutralizes respiratory syncytial virus and inhibits fusion with host cells ⓘ |
| hasMolecularType | humanized monoclonal antibody ⓘ |
| hasPharmacologicClass |
antiviral monoclonal antibody
ⓘ
immunologic agent ⓘ |
| hasPregnancyCategory | not established for use in pregnancy ⓘ |
| hasRouteOfAdministration |
intramuscular
ⓘ
parenteral ⓘ |
| hasSeriousAdverseEffect |
anaphylaxis
ⓘ
severe hypersensitivity reaction ⓘ |
| hasSideEffect |
fever
ⓘ
injection site reactions ⓘ rash ⓘ upper respiratory tract infection ⓘ |
| hasTargetPopulation |
high-risk infants
ⓘ
high-risk young children ⓘ |
| isAdministeredAs | monthly intramuscular injection during RSV season ⓘ |
| isAdministeredBy | healthcare professional ⓘ |
| isAdministeredDuring | RSV season ⓘ |
| isApprovedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| isContraindicatedIn | patients with history of severe hypersensitivity to palivizumab ⓘ |
| isGivenBy | intramuscular injection into anterolateral thigh ⓘ |
| isIndicatedFor |
certain high-risk children up to 24 months of age
ⓘ
infants with chronic lung disease of prematurity ⓘ infants with hemodynamically significant congenital heart disease ⓘ premature infants ⓘ |
| isMarketedBy | AstraZeneca NERFINISHED ⓘ |
| isNotRecommendedFor | routine use in healthy full-term infants ⓘ |
| isNotUsedFor |
treatment of acute RSV disease
ⓘ
treatment of established RSV infection ⓘ |
| isProducedBy | recombinant DNA technology ⓘ |
| isUsedFor | prophylaxis of RSV infection ⓘ |
| reduces | risk of RSV-related hospitalization in high-risk infants ⓘ |
| targets | respiratory syncytial virus NERFINISHED ⓘ |
| wasDevelopedBy | MedImmune NERFINISHED ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Synagis Description of subject: Synagis is a monoclonal antibody medication used to help prevent serious lower respiratory tract infections caused by respiratory syncytial virus (RSV) in high-risk infants and young children.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.